Artelo Biosciences (Artelo Biosciences) Total Stockholders Equity : $9.54 Mil (As of Mar. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Artelo Biosciences Total Stockholders Equity?

Artelo Biosciences's Total Stockholders Equity for the quarter that ended in Mar. 2024 was $9.54 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Artelo Biosciences's Book Value per Share for the quarter that ended in Mar. 2024 was $N/A. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Artelo Biosciences's Debt-to-Equity for the quarter that ended in Mar. 2024 was 0.01.

Artelo Biosciences Total Stockholders Equity Historical Data

The historical data trend for Artelo Biosciences's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Artelo Biosciences Total Stockholders Equity Chart

Artelo Biosciences Annual Data

Trend

Aug14

Aug15

Aug16

Aug17

Aug18

Aug19

Aug20

Aug21

Dec22

Dec23

Total Stockholders Equity

Get a 7-Day Free Trial

5.46

3.88

12.04

19.40

11.75

Artelo Biosciences Quarterly Data
	May19	Aug19	Nov19	Feb20	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Stockholders Equity	Get a 7-Day Free Trial															17.64	16.27	14.58	11.75	9.54

Artelo Biosciences (NAS:ARTLW) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Artelo Biosciences's Book Value per Share for the quarter that ended in Mar. 2024 is

Book Value per Share	=	(Total Stockholders Equity	-	Preferred Stock)	/	Shares Outstanding (EOP)
	=	(9.537	-	0)	/	0
	=	N/A

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Artelo Biosciences's Debt-to-Equity for the quarter that ended in Mar. 2024 is

Debt-to-Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.031	+	0.096)	/	9.537
	=	0.01

Artelo Biosciences Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of Artelo Biosciences's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Artelo Biosciences (Artelo Biosciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Artelo Biosciences Inc (NAS:ARTLW) » Definitions » Total Stockholders Equity

Comparable Companies

Traded in Other Exchanges

ARTL:USA

Address

505 Lomas Santa Fe, Suite 160, Solana Beach, CA, USA, 92075

Website

https://www.artelobio.com

Artelo Biosciences Inc is a United States-based development-stage biopharmaceutical company. It is engaged in development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, a family of receptors and neurotransmitters that form a biochemical communication network in body. It is focused on discovering, licensing, developing and commercializing treatments that control endocannabinoid system. The company pursues technologies and programs that offer proprietary approaches to cannabinoid-based therapies, also those derived from the cannabis plant and synthetic cannabinoids, as well as new chemical entities and compounds. The firm's flagship program is designed to be a patent-protected cannabinoid drug combination treatment for a rare and orphan disease.